The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation.
about
A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint InflammationDrug-induced blood pressure increase - recommendations for assessment in clinical and non-clinical studies.Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond.Small-molecule inhibitors of spleen tyrosine kinase as therapeutic agents for immune disorders: will promise meet expectations?Endothelial dysfunction and vascular disease - a 30th anniversary update.In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib.Syk inhibitors in clinical development for hematological malignancies.Prevention of fostamatinib-induced blood pressure elevation by antihypertensive agents.Quantifying the relationship between inhibition of VEGFR-2, drug-induced blood pressure elevation and hypertension.Fostamatinib for the Treatment of Adult Persistent and Chronic Immune Thrombocytopenia: Results of Two Phase 3, Randomized, Placebo-Controlled Trials.Fostamatinib for persistent/chronic adult immune thrombocytopenia.Rip2 modifies VEGF-induced signalling and vascular permeability in myocardial ischaemia.Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group studExposure vs. response of blood pressure in patients with rheumatoid arthritis following treatment with fostamatinib.Role of the Spleen Tyrosine Kinase Pathway in Driving Inflammation in IgA Nephropathy
P2860
Q28552367-2FBADA3C-2B46-4580-96B0-0C0FD72058EEQ30395099-4FCEB03C-8219-43ED-A8AE-9D7EFDD42B02Q33620537-3D9B3A21-D6C0-43D4-9492-E6083BEC46F3Q35434205-B4698555-E04D-49B6-92B0-7FCECD58956EQ38680112-4C3B6A41-9586-48F1-A8BB-BC2BAF018D50Q41773428-57E58BB1-DB61-4687-8408-6051B73D188FQ42011012-14957A58-973D-4CE9-927F-6FEF99F7AFD4Q43203308-8B948D3B-034F-441D-8113-B07E08A0FC2CQ47434764-D5EB1BA8-BF4B-4357-B8E0-1C0DFAC2FA07Q52562217-F3634F83-BDCB-49DE-9AF6-D75001D47BB0Q54144290-86EEDCFF-50A2-40B1-BAD5-241A54856804Q54261978-27BAD748-1859-4515-809E-88F2B4486810Q54322103-BC4E826A-0E92-4F45-AEA2-6F8C611AA240Q54347638-3482DE9C-9CE3-420D-93D1-FB0B87F3DFB2Q58775138-4BC07BAF-9808-4811-8190-1919D7BDD420
P2860
The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation.
@en
type
label
The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation.
@en
prefLabel
The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation.
@en
P2093
P2860
P356
P1476
The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation.
@en
P2093
A R Harmer
E Lamm Bergström
H Musgrove
J O Curwen
L Coverley
M Braddock
P2860
P304
P356
10.1111/BPH.12559
P407
P577
2014-05-01T00:00:00Z